An observational study in Lung Cancer (Diagnosis) and Circulating Tumor Cell, sponsored by Samsung Medical Center. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-08-28.
Sponsored by Samsung Medical Center · Observational
Among 22 studies in Lung Neoplasms by Samsung Medical Center — 5 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Samsung Medical Center.
Among the 22 studies in Lung Neoplasms by Samsung Medical Center, this one is the 10th largest by enrollment of the 12 observational ones, is one of 2 that started in 2018, is one of 12 observational ones, and was the 10th registered.
5,422 studies on the registry are indexed under Lung Neoplasms; 1,346 are open to participants now.
This study's enrollment of 111 is below the median of 200 across 1,434 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →5 of the 22 studies in Lung Neoplasms by Samsung Medical Center are open now, in 1 country. Each count lists the studies.
Of the 996 Lung Neoplasms studies recruiting now, 683 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →22 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2018.
Median enrollment 128 across the 10 interventional studies, 390 across the 12 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
Samsung Medical Center is the lead sponsor of 1,011 studies on the registry; 152 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
2 of the studies in Lung Neoplasms by Samsung Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07772804Samsung Medical CenterEffect of Mechanical Power-based Lung-protective Ventilation During One-lung Ventilation | 2027-08-30 |
| NCT04591002Samsung Medical CenterOsimertinib to Suppress the Progression of GGN(EGFR Mutation-positive) | 2027-09-01 |
Among the 22 studies in Lung Neoplasms by Samsung Medical Center, from their registry updates:
The purpose of this study is to assess clinical utility of combined circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) in the diagnosis of primary lung cancer.
The peripheral blood and tumor tissue samples are collected from the participants.CTC and ctDNA are analyzed from the blood samples.
The subjects who are referred for the evaluation and management of primary lung cancer in the tertiary care center
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic sensitivity of combined CTC and ctDNA
To compared the sensitivity of combined CTC and ctDNA with those of CTC and ctDNA alone in diagnosis of primary lung cancer
Time frame: 1 year
Diagnostic accuracy of combined CTC and ctDNA
To compared the accuracy of combined CTC and ctDNA with those of CTC and ctDNA alone in diagnosis of primary lung cancer
Time frame: 1 year
Diagnostic specificity of CTC and ctDNA
To compared the specificity of combined CTC and ctDNA with those of CTC and ctDNA alone in diagnosis of primary lung cancer
Time frame: 1 year
Plan to share: No
Ran from Mar 2018 to primary completion in Mar 2019, 11 months.
Of 591 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's 11 months is below that.
Counting every sponsor, half of 681 studies reached it within 57 months; a quarter within 25 and three quarters within 135.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.